MetaCap

Daxor (DXR) vs Xtant Medical (XTNT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Daxor (DXR) has outperformed Xtant Medical (XTNT) over the past year, losing 43.5% versus a loss of 66.1%. Over five years, DXR leads with a -32.3% price change compared with -73.1% for XTNT. Daxor is the larger company by market cap ($43.5 million vs $29.5 million), about 1.5 times the size, while Xtant Medical is growing revenue faster (+14.2% vs -8.4%).

Xtant Medical converts more of its revenue into profit, with a net margin of 3.7% versus -496.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DXR-43.52%XTNT-66.13%
+36%-18%-72%
Nov 21, 20251 yearNov 20, 2026
DXR-32.27%XTNT-76.40%
+55%-14%-83%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DXR versus XTNT key metrics
MetricDXRXTNT
Share price$7.45$0.21
Market cap$43.49M$29.49M
1-day change-7.33%-2.82%
YTD return-49.49%-73.08%
1-year return-43.52%-66.13%
5-year return-32.27%-73.08%
P/E ratio (TTM)6.77—
EPS (TTM)$1.10$-0.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.45M$133.93M
Revenue growth (YoY)-8.42%+14.21%
Net income (latest FY)$-7.19M$4.97M
Gross margin54.89%62.92%
Operating margin-400.07%5.44%
Net margin-496.81%3.71%
52-week high$14.76$0.84
52-week low$6.94$0.17
Distance from 52-week high-49.53%-75.00%
Analyst consensusnonenone
Avg. price target upside+168.46%+390.48%
Average volume22.43K1.69M
Shares outstanding5.84M140.45M
Employees—151
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DXR has outperformed XTNT by 22.6 percentage points over the past year.
  • Xtant Medical is more profitable, keeping 3.7 cents of every revenue dollar as net income versus -496.8 cents for Daxor.
  • Xtant Medical grew revenue faster in its latest fiscal year (+14.21% vs -8.42%).

About Daxor

DXR stock →

Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit.

Health Care · Medical/Dental Instruments

About Xtant Medical

XTNT stock →

Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally.

Health Care · Medical/Dental Instruments · 151 employees

DXR vs XTNT FAQ

Which is bigger, Daxor or Xtant Medical?

Daxor (DXR) is larger, with a market capitalization of $43.49M compared with $29.49M for Xtant Medical (XTNT).

Which stock has performed better over the past year, DXR or XTNT?

DXR returned -43.52% over the past 12 months, compared with -66.13% for XTNT (price return, excluding dividends). Past performance does not predict future results.

Are Daxor and Xtant Medical in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons